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Here, we report a case of thrombocytopenia induced by rhG-CSF administration in a healthy donor with no evidence of splenomegaly before apheresis started. The 51-year-old brother of a man with multiple myeloma was selected as matched donor for transplantation. Medical history included two episodes of Quincke's oedema, the first at the age of 33 years after cephalosporine administration, and the second at the age of 43 years after nimesulide. Clinical examination, chest X-ray, electrocardiogram, blood chemistry and urine analysis were normal. Serology was negative for hepatitis A, B and C viruses, HIV-1, herpes virus types 1 and 2 and toxoplasma. IgG tests were positive for cytomegalovirus and the EpsteinBarr virus. After providing informed consent, the donor was admitted to hospital for s.c. infusion of rhG-CSF (lenograstim 12 mg/kg body wt per day). WBC and plt counts and haemoglobin level were monitored before starting haematopoietic stem cell mobilization and daily during mobilization and collection (Figure 1 ). The plt count started to drop on day 1 of rhG-CSF administration, and three blood samples on day 4 provided plt counts of 77 Â 10 9 /l, 69 Â 10 9 /l and 63 Â 10 9 /l, respectively. As this donor was the only one in the patient's family, and the CD34 þ cell count was sufficient, the leukapheresis procedures were performed with a continuous flow blood cell separator (COBE Spectra, Lakewood, CO, USA). The plt count was 37 Â 10 9 /l afterwards. On day 6, the plt count of 78 Â 10 9 /l before leukapheresis had fallen into 30 Â 10 9 /l later. On day 7, as the plt count was 27 Â 10 9 /l, leukapheresis procedures were suspended and the plt count monitored. On days 8 and 9, it was unchanged. On day 10 (72 h after suspending rhG-CSF), it started to rise slightly, reaching 50 Â 10 9 /l whereupon the patient was discharged from hospital. On day 16 (9 days after stopping rhG-CSF), the plt count rebounded to 268 Â 10 9 /l. Pretreatment plt counts were reached on day 37. Screening for autoimmune disease, including detection of anti-plt antibodies, was negative. Three abdominal ultrasound scans showed no splenomegaly. As the CD34 þ cell harvest was insufficient to constitute a graft, BM was explanted from the donor. Checkups for 1 year after rhG-CSF administration showed normal blood parameters.
During haematopoietic stem cell mobilization in healthy donors, slight thrombocytopenia is common and is attributed to the leukapheresis procedure or to splenomegaly. The plt depletion is a recognized effect of continuous flow leukapheresis, particularly large-volume leukapheresis. 1 Indeed, in our large series of healthy donors, we observed significant drops in plt counts after 3-4 leukapheresis sessions. In animal models and in humans, rhG-CSF administration was followed by a varying incidence and grade of splenomegaly, 2 with differences in assessment methods underlying some of the divergent results. A previous study 3 reported that the spleen enlargement was detected by palpation in 17% of subjects by ultrasound measurement of longitudinal diameter in 60% and by ultrasound calculations of spleen volume in 91%. In patients with enlarged spleen, splenic pooling of plts leads to thrombocytopenia, perhaps due to splenic hyperactivity. This hypothesis was not confirmed in animal models or in clinical observations as demonstrated by others 4, 5 who showed that in humans, spleen size does not correlate with abnormalities in haematological parameters. Several authors described drops in plt counts, which did not reach the pathological threshold during rhG-CSF treatment before leukapheresis, 6 and as far as we know, only two cases of low plt counts were directly linked to rhG-CSF administration-one in a patient with the Felty syndrome 7 and the other with an underlying immune-mediated thrombocytopenia. 8 In this case, plt counts became abnormally low during rhG-CSF administration, and we are of the view that the drop was directly linked to therapy, as the marked reduction was observed before starting leukapheresis and there was no ultrasound evidence of splenomegaly. In conclusion, the low plt count in our patient appears to be directly linked to rhG-CSF administration. The patient's history of allergic reactions to some drugs, which may have enhanced the rhG-CSF plt-lowering effect suggests that the caution and close monitoring of haematological parameters are warranted when donors have a similar history. The abnormally low plt count in this donor did not prejudice haematopoietic stem cell collection, and was short term and resolved spontaneously.
